Collectively, these findings indicated that CDK4/6 inhibitor combined with endocrine therapy is effective in treating HR+/HER2-low breast cancer, but with lower efficacy compared with HR+/HER2-0 breast cancer. Here, ERBB2 is linked to breast carcinoma.